Banach-Wawrzeńczyk E, Dziedziczko A, Rość D
Department of Allergology and Internal Diseases, Medical University, ul. Ujejskiego 75, 85-168 Bydgoszcz, Poland.
Med Sci Monit. 2000 Jan-Feb;6(1):103-7.
Every inflammatory process, including that in the course of bronchial asthma may disturb the balance in blood coagulation and fibrinolysis system. The aim of the present study was to evaluate fibrinolysis in patients with bronchial asthma. The study group consisted of 41 patients with bronchial asthma, hitherto untreated (25 women, 16 men, at mean age 37.37 +/- 12.4 years) and 22 healthy adults (control group). In these subjects, the following parameters were established: euglobulin lysis time (ELT), the concentration of tissue plasminogen activator antigen (t-PA Ag), the concentration of urokinase plasminogen activator antigen (u-PA Ag), the activity of plasminogen activator inhibitor type 1 (PAI-1), the concentration of plasmin-antiplasmin complex (PAP) and fibrinogen/fibrin degradation products (FDP). It was found that patients with bronchial asthma had statistically significantly higher mean values of FDP (9.25 +/- 6.7 micrograms/ml vs. 5.0 +/- 5.9 micrograms/ml; p < 0.001), ELT (123.5 +/- 42.7 min vs. 97.4 +/- 27.1 min; p < 0.001), t-PA Ag (8.36 +/- 3.66 ng/ml vs. 5.5 +/- 3.71 ng/ml; p < 0.01) and PAP complexes (250.3 +/- 95.8 ng/ml vs. 193.4 +/- 60.7 ng/ml; p < 0.02). Mean u-PA Ag concentration in patients with bronchial asthma was significantly lower than in control group (0.24 +/- 0.16 ng/ml vs. 0.53 +/- 0.18 ng/ml; p < 0.01). No statistically significant differences were observed as to PAI-1 activity between patients with bronchial asthma and healthy subjects. The results of the present study suggest that increased concentrations of t-PA Ag, PAP and FDP complexes are the evidence for greater activity of fibrinolysis system in subjects with bronchial asthma.
每一种炎症过程，包括支气管哮喘病程中的炎症过程，都可能扰乱血液凝固和纤维蛋白溶解系统的平衡。本研究的目的是评估支气管哮喘患者的纤维蛋白溶解情况。研究组由41例未经治疗的支气管哮喘患者（25名女性，16名男性，平均年龄37.37±12.4岁）和22名健康成年人（对照组）组成。在这些受试者中，测定了以下参数：优球蛋白溶解时间（ELT）、组织纤溶酶原激活物抗原（t-PA Ag）浓度、尿激酶型纤溶酶原激活物抗原（u-PA Ag）浓度、1型纤溶酶原激活物抑制剂（PAI-1）活性、纤溶酶-抗纤溶酶复合物（PAP）浓度以及纤维蛋白原/纤维蛋白降解产物（FDP）。结果发现，支气管哮喘患者的FDP平均值（9.25±6.7微克/毫升 vs. 5.0±5.9微克/毫升；p<0.001）、ELT（123.5±42.7分钟 vs. 97.4±27.1分钟；p<0.001）、t-PA Ag（8.36±3.66纳克/毫升 vs. 5.5±3.71纳克/毫升；p<0.01）和PAP复合物（250.3±95.8纳克/毫升 vs. 193.4±60.7纳克/毫升；p<0.02）在统计学上显著更高。支气管哮喘患者的u-PA Ag平均浓度显著低于对照组（0.24±0.16纳克/毫升 vs. 0.53±0.18纳克/毫升；p<0.01）。支气管哮喘患者与健康受试者之间在PAI-1活性方面未观察到统计学上的显著差异。本研究结果表明，t-PA Ag、PAP和FDP复合物浓度升高是支气管哮喘患者纤维蛋白溶解系统活性增强的证据。
